Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
GENILGen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey. Address: Mustafa Kemal District 2119, Çankaya, Turkey, 06520
Analytics
Precio Objetivo de WallStreet
4 331.95 TRYRelación P/E
45.26Rentabilidad por dividendo
0.74 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave GENIL
Análisis de dividendos GENIL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
21.00 %Tendencia del payout GENIL
Valoración de la acción GENIL
Finanzas GENIL
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |